Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma

BACKGROUND: Leiomyosarcoma (LMS) accounts for 24% of all soft tissue sarcomas (STSs) and this STS subtype has high metastatic potential. Previous studies indicated the best median progression-free survival (mPFS) time was 9.2 months and the best overall response rate (ORR) was 30.9%. We evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Huijing, Zuo, Lijie, Ma, Shutao, Wang, Dingyuan, Li, Rui, Yang, Yiqi, Liu, Weili, Chi, Yihebali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672029/
https://www.ncbi.nlm.nih.gov/pubmed/34916850
http://dx.doi.org/10.2147/CMAR.S342213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672029/
https://www.ncbi.nlm.nih.gov/pubmed/34916850
http://dx.doi.org/10.2147/CMAR.S342213

Ejemplares similares